» Articles » PMID: 31038962

Exosome-like Nanoparticles from Ginger Rhizomes Inhibited NLRP3 Inflammasome Activation

Overview
Journal Mol Pharm
Specialty Pharmacology
Date 2019 May 1
PMID 31038962
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

The nucleotide-binding domain and leucine-rich repeat-containing family, pyrin domain-containing 3 (NLRP3) inflammasome is a key regulator of innate immune responses, and its aberrant activation is implicated in the pathogenesis of many diseases such as Alzheimer's disease and type 2 diabetes. Targeting the NLRP3 inflammasome could hold promise to combat these complex diseases, but therapies specifically inhibiting the NLRP3 inflammasome have not been developed for patient treatment. The current study aimed to identify food-borne exosome-like nanoparticles (ELNs) that inhibit NLRP3 inflammasome activity. Nine vegetables or fruits were selected to extract ELNs, which were examined for their inhibitory effects on activation of the NLRP3 inflammasome in primary macrophages. Although most of the tested ELNs posed minimal impacts, the ELNs from ginger rhizomes (G-ELNs) strongly inhibited NLRP3 inflammasome activation. The G-ELNs contained lipids, proteins, and RNAs and were easily taken up by macrophages. G-ELN treatment suppressed pathways downstream of inflammasome activation including caspase1 autocleavage, interleukin (IL)-1β and IL-18 secretion, and pyroptotic cell death. Apoptotic speck protein containing a caspase recruitment domain (ASC) oligomerization and speck formation assays indicated that G-ELNs blocked assembly of the NLRP3 inflammasome. The lipids in G-ELNs, rather than the RNAs or proteins, were responsible for the inhibitory activity observed. Together, the data suggested G-ELNs as new potent agents that block NLRP3 inflammasome assembly and activation. The unique features of G-ELNs including biomolecule protection and tissue bioavailability should facilitate the development of G-ELN-based therapy to target the NLRP3 inflammasome in the disease settings.

Citing Articles

Isolation, Characterization, and In Vitro Cell Studies of Plant-Based Exosome-like Nanovesicles for Treatment of Early Osteoarthritis.

Rashidi N, Liu C, Guillot P, Tamaddon M Int J Mol Sci. 2025; 26(5).

PMID: 40076829 PMC: 11900001. DOI: 10.3390/ijms26052211.


Polypharmacology and Neuroprotective Effects of Gingerol in Alzheimer's Disease.

Priyadarshini S, Goyal K, R R, Gupta S, Roy A, Biswas R Mol Neurobiol. 2025; .

PMID: 39982688 DOI: 10.1007/s12035-024-04484-y.


Harnessing tomato-derived small extracellular vesicles as drug delivery system for cancer therapy.

Sarwareddy K, Singh A, Patnam S, Sesuraj B, Ponamgi S, Thakur B Future Sci OA. 2025; 11(1):2461956.

PMID: 39920889 PMC: 11812386. DOI: 10.1080/20565623.2025.2461956.


Folic acid-modified ginger-derived extracellular vesicles for targeted treatment of rheumatoid arthritis by remodeling immune microenvironment via the PI3K-AKT pathway.

Han R, Zhou D, Ji N, Yin Z, Wang J, Zhang Q J Nanobiotechnology. 2025; 23(1):41.

PMID: 39849554 PMC: 11756199. DOI: 10.1186/s12951-025-03096-5.


Gold Kiwi-Derived Nanovesicles Mitigate Ultraviolet-Induced Photoaging and Enhance Osteogenic Differentiation in Bone Marrow Mesenchymal Stem Cells.

Kim D, Lee C, Kim M, Park J Antioxidants (Basel). 2025; 13(12.

PMID: 39765803 PMC: 11673108. DOI: 10.3390/antiox13121474.